Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension *: a 1-year follow-up study. (clinical investigations)

Authors :: Sitbon, Olivier
Badesch, David B.
Channick, Richard N.
Frost, Adaani
Robbins, Ivan M.
Simonneau, Gerald
Tapson, Victor F.
Rubin, Lewis J.
Source :: Chest. July 2003, Vol. 124 Issue 1, p247, 8 p.
Publication Year :: 2003
Abstract: Study objectives: We report on the long-term safety and efficacy of bosentan treatment in patients with pulmonary arterial hypertension (PAH). Background: In a preceding study, bosentan was well tolerated and [...]

Subjects :: Systemic scleroderma -- Health aspects -- Causes of -- Care and treatment -- Research -- Drug therapy -- Case studies -- Methods -- Physiological aspects -- Analysis
Medical research -- Analysis -- Methods -- Case studies -- Physiological aspects -- Health aspects
Medicine, Experimental -- Analysis -- Methods -- Case studies -- Physiological aspects -- Health aspects
Endothelin -- Physiological aspects -- Dosage and administration -- Case studies -- Research -- Analysis -- Methods -- Health aspects
Scleroderma (Disease) -- Health aspects -- Causes of -- Care and treatment -- Research -- Drug therapy -- Case studies -- Methods -- Physiological aspects -- Analysis
Chest -- Diseases
Drugs -- Physiological aspects -- Dosage and administration -- Case studies -- Research -- Health aspects -- Methods -- Analysis
Methodology -- Analysis -- Case studies -- Methods -- Physiological aspects -- Health aspects
Hospital patients -- Health aspects -- Care and treatment -- Case studies -- Drug therapy -- Analysis -- Methods -- Physiological aspects
Pulmonary hypertension -- Health aspects -- Care and treatment -- Drug therapy -- Research -- Case studies -- Analysis -- Physiological aspects -- Methods
Health
Drug therapy
Care and treatment
Analysis
Physiological aspects
Case studies
Research
Methods
Dosage and administration
Health aspects
Causes of

Tools